share_log

Vivos Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Huntsman Ronald Kirk

SEC ·  Jun 29 08:57
Summary by Futu AI
Ronald Kirk Huntsman, the Chief Executive Officer of Vivos Therapeutics, Inc. [VVOS], has been reported to hold a total of 73,061 shares in the company following recent transactions. The transactions, which took place on June 20, 2024, involved common stock and resulted in Huntsman holding 3,461 shares directly and 69,600 shares indirectly. The nature of the indirect ownership is detailed in a footnote, which is not disclosed in this summary. The report emphasizes the CEO's continued investment in the company's stock, which could be of interest to current and potential investors.
Ronald Kirk Huntsman, the Chief Executive Officer of Vivos Therapeutics, Inc. [VVOS], has been reported to hold a total of 73,061 shares in the company following recent transactions. The transactions, which took place on June 20, 2024, involved common stock and resulted in Huntsman holding 3,461 shares directly and 69,600 shares indirectly. The nature of the indirect ownership is detailed in a footnote, which is not disclosed in this summary. The report emphasizes the CEO's continued investment in the company's stock, which could be of interest to current and potential investors.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.